SGLT2i inhibitors offer better outcomes than DPP4 inhibitors

      Sodium glucose cotransporter-2 inhibitors (SGLT2i) and dipeptidyl peptidase-4 inhibitors (DPP4i) are now widely for the treatment of diabetes. A recent study published in ‘Diabetes Research and Clinical Practice’ revealed that SGLT2i provides better cardiorenal outcomes and lowers mortality rates than DPP4i.

The researchers selected patients with T2D from an administrative claims database of > 5.2M citizen who initiated SGLT2i or DPP4i from 2014 to 2018. Patients were matched by propensity scores. The primary outcome was the 3-point major adverse cardiovascular events (3P-MACE). The study results showed that during a median follow-up of 18 months, the rate of 3P-MACE was lower among patients who initiated SGLT2i vs. DPP4i. Initiators of SGLT2i also showed significantly lower rates of myocardial infarction, hospitalization for heart failure or cardiovascular causes, and all-cause death (HR 0.49; 95 %C.I. 0.25–0.95). It was also noted that renal failure was less common with SGLT2i than with DPP4i.

Based on the findings the study concluded that patients with T2D who initiated SGLT2i under routine care had better cardio-renal outcomes and lower all-cause mortality than similar patients who initiated DPP4i.

Read More